[SimBioSys] SimBioSys® announced US FDA 510(k) clearance of TumorSight® Risk, the world’s first AI-powered, MRI-derived prognostic tool for assessing breast cancer recurrence risk.

[Prelude Therapeutics Incorporated] Prelude Therapeutics Incorporated announced a clinical trial collaboration and supply agreement with Eli Lilly and Company (“Lilly”) for supply of its CDK4/6 kinase inhibitor, abemaciclib and its oral estrogen receptor antagonist, imlunestrant.

[Pfizer Inc. (BusinessWire)] Pfizer Inc. announced that the US FDA has approved TUKYSA® (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive (HER2+) breast cancer following induction treatment.

[American Journal of Human Genetics] Scientists collated and harmonized results from 185 individual instances of functional assays for 3,247 missense variants in BRCA1 and 147 individual instances of functional assays for 6,177 missense variants in BRCA2 to construct Functional Assay Integration databases.

[Pharmacological Research] Investigators demonstrated that laminarin, a biocompatible β-1,3-glucan extracted from brown algae, exerts significant antitumor immune effects against TNBC with no evident toxicity under the tested conditions.

[elife] Researchers highlighted JAK-STAT pathway's (JSP) functional heterogeneity in epithelial, tumor, and T cells. JSP is regarded as one of the major abnormally activated oncogenic pathways in breast cancer.

[International Journal of Biological Macromolecules] Scientists evaluated the biological effects of two distinct β-D-glucans purified from an alkaline extract of the mushroom Lactarius quieticolor in vitro using non-tumorigenic HB4a and tumorigenic MDA-MB-231 human breast cells.

[OncoImmunology] The authors investigated how estrogen shapes the extracellular microenvironment of the normal human breast, combining in vivo microdialysis of breast tissue from healthy pre- and postmenopausal women with high-dimensional proteomic profiling

[Molecular Cancer Therapeutics] Researchers evaluated whether polo-like kinase 1 (PLK1) inhibition with onvansertib enhances paclitaxel activity in hormone receptor-positive (HR+) breast cancer models with intrinsic or acquired endocrine therapy/CDK4/6 inhibitor resistance.

[Proteomics] Scientists reported a comprehensive proteomics analysis of mixed membrane fraction isolated by ultracentrifugation from TNBC cell lines with different tumor node metastasis stages compared to the healthy MCF-12F breast cell line.

[The Journal of Steroid Biochemistry and Molecular Biology] The authors proposed the interaction of petromurin C with estrogen receptor alpha (ERα) using surface plasmon resonance, revealing biphasic dissociation kinetics.

[Translational Oncology] Ephrin type-A receptor 2 (EphA2) undergoes membrane-type 1 matrix metalloproteinase (MMP14)-mediated cleavage that releases soluble N-terminal fragments. Researchers investigated the diagnostic and functional significance of this fragment in TNBC.